Defining Biological Subsets in Systemic Lupus Erythematosus: Progress Toward Personalized Therapy.
- Published in:
- Pharmaceutical Medicine, 2017, v. 31, n. 2, p. 81, doi. 10.1007/s40290-017-0178-6
- By:
- Publication type:
- Article
Works matching IS 11782595 AND DT 2017 AND VI 31 AND IP 2
Results: 8
1
2
Major Pharmaceutical Conferences and Courses.
- Published in:
- Pharmaceutical Medicine, 2017, v. 31, n. 2, p. 139, doi. 10.1007/s40290-017-0179-5
- Publication type:
- Article
3
An Evaluation of the Effectiveness of Risk Minimization Measures for Tigecycline in the European Union.
- Published in:
- Pharmaceutical Medicine, 2017, v. 31, n. 2, p. 89, doi. 10.1007/s40290-017-0180-z
- By:
- Publication type:
- Article
4
Forum.
- Published in:
- Pharmaceutical Medicine, 2017, v. 31, n. 2, p. 125, doi. 10.1007/s40290-017-0181-y
- Publication type:
- Article
5
Correlation Between Elimination Parameters of Phenytoin and Carbamazepine in Patients with Epilepsy Receiving Both Drugs Concomitantly: A Preliminary Study.
- Published in:
- Pharmaceutical Medicine, 2017, v. 31, n. 2, p. 119, doi. 10.1007/s40290-017-0182-x
- By:
- Publication type:
- Article
6
Considerations for Good Pharmacovigilance Outsourcing Practices.
- Published in:
- Pharmaceutical Medicine, 2017, v. 31, n. 2, p. 75, doi. 10.1007/s40290-017-0183-9
- By:
- Publication type:
- Article
7
Additional Risk Minimisation Measures for Medicinal Products in the European Union: A Review of the Implementation and Effectiveness of Measures in the United Kingdom by One Marketing Authorisation Holder.
- Published in:
- Pharmaceutical Medicine, 2017, v. 31, n. 2, p. 101, doi. 10.1007/s40290-017-0184-8
- By:
- Publication type:
- Article
8
Quantitative Methods for Safety Monitoring of Rare Serious Adverse Events.
- Published in:
- Pharmaceutical Medicine, 2017, v. 31, n. 2, p. 113, doi. 10.1007/s40290-016-0176-0
- By:
- Publication type:
- Article